ReviewStem cell reviews and reports2026
Advancing Congenital Heart Defect Treatments: Synergistic Approaches with Stem Cells and Functional Scaffolds.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital heart defects (CHDs), ranging from minor issues to critical malformations requiring urgent and ongoing medical care, are structural heart abnormalities present at birth. Historically, the prognosis for CHD patients was poor; however, advancements in medical treatments have significantly improved survival rates, with approximately 90% of children with CHDs now reaching adulthood. Standard CHD treatments include cardiac catheterization, heart surgery, medications, and, in severe cases, heart transplantation. Despite these advancements, innovative approaches are urgently needed to enhance therapeutic outcomes and overcome the limitations of current treatments. Recently, the integration of stem cell technologies with bio-scaffold engineering has garnered substantial attention. Key breakthroughs include the development of resilient biological scaffolds designed to expand and remodel within the heart, potentially overcoming the limitations of existing prostheses. Promising regenerative CHD treatments emerge from decellularized extracellular matrix scaffolds combined with autologous stem cells. Tissue engineering and pre-vascularization technologies aim to create functional heart tissues capable of growing with the child, thus reducing the need for multiple procedures. Enhanced scaffold fabrication techniques, such as 3D bioprinting, nanofiber scaffolds, and biomimetic fixation methods, have significantly advanced the field. These technologies enable better integration with native cardiac tissues and allow precise control over scaffold properties. Additionally, innovations in hybrid and smart scaffolds, along with bioreactor conditioning, further amplify the regenerative potential of engineered cardiac tissues. This review focuses on the convergence of stem cell therapy and bio-scaffold technology, highlighting the latest advancements in CHD treatment. It explores the evolution of novel materials and methodologies aimed at creating flexible, durable solutions for managing CHDs. By combining regenerative medicine with cutting-edge scaffold engineering, these emerging therapies offer hope for improved outcomes and quality of life for individuals affected by CHDs.
Indexed as
Identifiers
41114896What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.